Royalty Pharma plc (RPRX) Return on equity 2018–2025
Royalty Pharma plc (RPRX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
7.9%FY2025 · since FY2018: 30.3% → 7.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 7.9% | -0.4 pp |
| FY2024 | 8.3% | -2.9 pp |
| FY2023 | 11.3% | +10.8 pp |
| FY2022 | 0.4% | -5.6 pp |
| FY2021 | 6.0% | -3.8 pp |
| FY2020 | 9.9% | -28.4 pp |
| FY2019 | 38.2% | +8.0 pp |
| FY2018 | 30.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More RPRX financial trends
RPRX RevenueRPRX Net incomeRPRX Net marginRPRX Gross profitRPRX Gross marginRPRX Operating incomeRPRX Operating marginRPRX Operating cash flowRPRX Free cash flowRPRX Capital expendituresRPRX Stock buybacksRPRX Dividends paidRPRX Total assetsRPRX Total liabilitiesRPRX Shareholders’ equityRPRX overview →